Browse diseases

…Background Migraine is a common comorbidity in patients with cervical dystonia (CD); however, the diagnosis of chronic migraine (CM) in patien…

…elevance Results suggest that the effectiveness of atogepant in chronic migraine, in terms of reducing monthly migraine days, is comparable betw…

…t using IBM SPSS.Results Thirty-eight patients (89% women) with CM (95%) and HFEM (5%) were included, with a median age of 45 [ran…

…ECMO.Conclusions Heart failure is the leading cause of death in CAHD, followed by PH, with most deaths occurring within the first ye…

…portance Atogepant is indicated for the preventive treatment of chronic migraine (CM), a highly prevalent and disabling neurological disorder. It is …

…those at the highest risk of death. Patients with node-negative CM and a high-risk 31-GEP result may benefit from more intensive s…

…f gepants (atogepant and rimegepant) in patients diagnosed with CM and HFEM naive versus those previously treated with anti-CGRP m…

…ts calcitonin gene-related peptide (CGRP) receptors involved in migraine development.Aim and Objectives To evaluate atogepant effectiven…

…eviously received fremanezumab; 80% (n=24) had CM and 20% (n=6) HFEM. Median treatment duration was 5 months (1–13). Twelve patients…

…Introduction Refractory chronic migraine (RCM) is defined as experiencing 15 headache days per month des…

…ty in treatment-refractory advanced cutaneous melanoma (CM) and synovial sarcoma (SS); there are opportunities to further improve outcomes in th…